Syndax Pharmaceuticals Return On Equity vs. Return On Asset
| 1T3 Stock | EUR 12.80 0.10 0.78% |
For Syndax Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Syndax Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Syndax Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Syndax Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Syndax Pharmaceuticals over time as well as its relative position and ranking within its peers.
Syndax |
Syndax Pharmaceuticals Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Syndax Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Syndax Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Syndax Pharmaceuticals |
| = | -0.0519 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Syndax Pharmaceuticals |
| = | -0.0292 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Syndax Return On Asset Comparison
Syndax Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Syndax Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Syndax Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Syndax Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Syndax Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Syndax Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax Pharmaceuticals operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 38 people.
Syndax Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Syndax Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Syndax Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Syndax Pharmaceuticals' important profitability drivers and their relationship over time.
Use Syndax Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syndax Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Syndax Pharmaceuticals Pair Trading
Syndax Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Syndax Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syndax Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syndax Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syndax Pharmaceuticals to buy it.
The correlation of Syndax Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syndax Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syndax Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syndax Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Syndax Pharmaceuticals position
In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks Thematic Idea Now
Banks
Large and small money and credit banks and credit services. The Banks theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Trending Equities. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
To fully project Syndax Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Syndax Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Syndax Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.